{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:42:56Z","timestamp":1782452576120,"version":"3.54.5"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The treatment of patients with relapsed or refractory (R\/R) acute myeloid leukaemia (AML) has been an unequal challenge for many decades. Although significant progress has been made in the discovery of the mechanisms underlying the molecular pathogenesis of the disease, more than 50% of AML patients still die, mostly from relapsed disease. Currently, the only potential curative option for patients with R\/R AML remains allogeneic bone marrow transplantation in second complete remission, which is far being easy to achieve, mainly for patients with primary induction failure or older than 65\u200ayears. The purpose of this review is to discuss recent advances in the management of patients with R\/R AML, with particular emphasis to new therapeutic options that are replacing conventional salvage chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The development of new agents selectively targeting molecular abnormalities offer more effective and less toxic alternative to chemotherapy, potentially useful as a bridge to allogeneic stem cell transplantation in second complete remission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The recent approval of new drugs for R\/R is transforming the paradigm of care we have relied on for the past 50\u200ayears. Ongoing clinical trials will tell us how bright is the future for R\/R AML patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000780","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T08:41:48Z","timestamp":1630658508000},"page":"635-641","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["The changing landscape for patients with relapsed\/refractory acute myeloid leukaemia"],"prefix":"10.1097","volume":"33","author":[{"given":"Alessandro","family":"Isidori","sequence":"first","affiliation":[{"name":"Hematology and Stem Cell Transplantation, AORMN Hospital, Pesaro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicetto","family":"Ferrara","sequence":"additional","affiliation":[{"name":"Division of Hematology, Cardarelli Hospital, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.2019001982","article-title":"How I treat relapsed or refractory AML","volume":"136","author":"De Wolf","year":"2020","journal-title":"Blood"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-021-01230-4","article-title":"Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations","volume":"35","author":"Walter","year":"2021","journal-title":"Leukemia"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3324\/haematol.2010.027516","article-title":"Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse","volume":"95","author":"Kurosawa","year":"2010","journal-title":"Haematologica"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.25162","article-title":"Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience","volume":"93","author":"Ganzel","year":"2018","journal-title":"Am J Hematol"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/leu.2011.25","article-title":"A new Leukemia Prognostic Scoring System for refractory\/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study","volume":"25","author":"Chevallier","year":"2011","journal-title":"Leukemia"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/bjh.17426","article-title":"Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia","volume":"193","author":"Kharfan-Dabaja","year":"2021","journal-title":"Brit J Haematol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.bmt.1702519","article-title":"Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience","volume":"26","author":"Sierra","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/bmt.2016.188","article-title":"A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation","volume":"52","author":"Magenau","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1200\/JCO.2013.51.2913","article-title":"International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia","volume":"32","author":"Roboz","year":"2014","journal-title":"J Clin Oncol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1470-2045(15)00201-6","article-title":"Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study","volume":"16","author":"Ravandi","year":"2015","journal-title":"Lancet Oncol"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","article-title":"Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm.3522","article-title":"Tumor heterogeneity confounds and illuminates: assessing the implications","volume":"20","author":"Kleppe","year":"2014","journal-title":"Nat Med"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"R19-20250526","article-title":"Efficacy and safety of venetoclax in combination with gilteritinib for relapsed\/refractory flt3-mutated acute myeloid leukemia: updated analyses of a phase 1b study","author":"Altman","year":"2020","journal-title":"Presented at: EHA 2021 Virtual Congress, Oral Presentation"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-18-3749","article-title":"FDA approval summary: ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation","volume":"25","author":"Norsworthy","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3324\/haematol.2019.242826","article-title":"Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis","volume":"105","author":"Bewersdorf","year":"2020","journal-title":"Haematologica"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"656218","DOI":"10.3389\/fonc.2021.656218","article-title":"Immunotherapy in acute myeloid leukemia: where we stand","volume":"11","author":"Isidori","year":"2021","journal-title":"Front Oncol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:08:41Z","timestamp":1748300921000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000780","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]}}}